|
|
|
xi | |
| Introduction |
|
xv | |
|
I Applications Of Nutraceuticals In Common Diseases And Disorders |
|
|
|
1 Nutraceuticals in CNS Diseases: Potential Mechanisms of Neuroprotection |
|
|
3 | (12) |
|
|
|
|
|
|
|
|
|
2 Prevention of Neurodegenerative Disorders by Nutraceuticals |
|
|
15 | (14) |
|
|
|
|
|
3 Cognitive Effects of Nutraceuticals |
|
|
29 | (20) |
|
|
|
|
|
4 Nutraceuticals in Cardiovascular Diseases |
|
|
49 | (12) |
|
|
|
5 Antiatherosclerotic Efficacy of Nutraceuticals |
|
|
61 | (14) |
|
|
|
|
|
6 Nutraceuticals in Respiratory Disorders |
|
|
75 | (12) |
|
|
|
|
|
|
|
|
|
7 Nutraceuticals in Hepatic Diseases |
|
|
87 | (14) |
|
|
|
8 Nutraceuticals in Renal Diseases |
|
|
101 | (8) |
|
|
|
9 Nutraceuticals in Gastrointestinal Disorders |
|
|
109 | (14) |
|
|
|
|
|
10 Nutraceuticals in Reproductive and Developmental Disorders |
|
|
123 | (12) |
|
|
|
11 Nutraceuticals in Cancer Prevention |
|
|
135 | (10) |
|
|
|
|
|
|
|
|
|
12 Nutraceuticals in Glucose Balance and Diabetes |
|
|
145 | (16) |
|
|
|
13 Nutraceuticals in Arthritis |
|
|
161 | (16) |
|
|
|
14 Nutraceuticals in Sports Activities and Fatigue |
|
|
177 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15 Application of "Nano" Nutraceuticals in Medicine |
|
|
189 | (4) |
|
|
|
16 Nutraceuticals as Adaptogens: Their Role in Health and Disease |
|
|
193 | (16) |
|
|
|
|
|
|
|
II Models And Mechanisms In Evaluation Of Nutraceuticals |
|
|
|
17 The Biology of Nutrients: Genetic and Molecular Principles |
|
|
209 | (18) |
|
|
|
|
|
18 Genomic and Proteomic Mechanisms and Models in Toxicity and Safety Evaluation of Nutraceuticals |
|
|
227 | (12) |
|
|
|
|
|
|
|
|
|
19 Adverse Reaction Prediction and Pharmacovigilance of Nutraceuticals: Examples of Computational and Statistical Analysis on Big Data |
|
|
239 | (10) |
|
|
|
20 Gene Expression Profiling in Evaluating the Safety and Toxicity of Nutraceuticals |
|
|
249 | (14) |
|
|
|
|
|
|
|
|
|
|
|
21 Target Identification and Polypharmacology of Nutraceuticals |
|
|
263 | (24) |
|
|
|
|
|
|
|
|
|
22 Mechanistic Network Models in Safety and Toxicity Evaluation of Nutraceuticals |
|
|
287 | (18) |
|
|
|
|
|
|
|
|
|
23 Noninvasive In Vivo Optical Imaging Models for Safety and Toxicity Testing |
|
|
305 | (14) |
|
|
|
24 Flow Cytometry and Light Scattering Technique in Evaluation of Nutraceuticals |
|
|
319 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25 Zebrafish Model for Safety and Toxicity Testing of Nutraceuticals |
|
|
333 | (8) |
|
|
|
|
|
26 Caenorhabditis elegans: A Model Organism for Nutraceutical Safety and Toxicity Evaluation |
|
|
341 | (14) |
|
|
|
|
|
|
|
|
|
27 Alternative In Vitro Models for Safety and Toxicity Evaluation of Nutraceuticals |
|
|
355 | (32) |
|
|
|
|
|
28 Mitochondria as a Target for Safety and Toxicity Evaluation of Nutraceuticals |
|
|
387 | (14) |
|
|
|
|
|
|
|
|
|
29 Oxidative Stress and Excitotoxicity: Antioxidants from Nutraceuticals |
|
|
401 | (16) |
|
|
|
|
|
|
|
III COMMON NUTRACEUTICALS |
|
|
|
30 Caffeine: An Evaluation of the Safety Database |
|
|
417 | (18) |
|
|
|
|
|
435 | (12) |
|
|
|
|
|
|
|
447 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
33 Resveratrol: Multiple Activities on the Biological Functionality of the Cell |
|
|
453 | (12) |
|
|
|
34 Isoflavones: Toxicological Aspects and Efficacy |
|
|
465 | (24) |
|
|
|
|
|
|
|
|
|
|
|
489 | (12) |
|
|
|
|
|
|
|
36 Melatonin: A Safe Nutraceutical and Clinical Agent |
|
|
501 | (10) |
|
|
|
|
|
37 Arginine and Citrulline as Nutraceuticals: Efficacy and Safety in Diseases |
|
|
511 | (20) |
|
|
|
|
|
38 Astaxanthin: Health Benefits and Toxicity |
|
|
531 | (10) |
|
|
|
|
|
541 | (10) |
|
|
|
|
|
|
|
|
|
551 | (4) |
|
|
|
41 Organosulfur Compounds as Nutraceuticals |
|
|
555 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
569 | (16) |
|
|
|
|
|
|
|
|
|
585 | (14) |
|
|
|
|
|
|
|
44 Fenugreek: Multiple Health Benefits |
|
|
599 | (20) |
|
|
|
|
|
619 | (14) |
|
|
|
|
|
|
|
633 | (20) |
|
|
|
|
|
|
|
653 | (16) |
|
|
|
|
|
669 | (12) |
|
|
|
|
|
|
|
|
|
|
|
681 | (12) |
|
|
|
|
|
|
|
693 | (14) |
|
|
|
|
|
|
|
707 | (10) |
|
|
|
|
|
|
|
52 Ashwagandha: Multiple Health Benefits |
|
|
717 | (18) |
|
|
|
|
|
|
|
53 Cannabis sativa and Hemp |
|
|
735 | (22) |
|
|
|
|
|
|
|
|
|
IV Prebiotics And Probiotics |
|
|
|
54 Prebiotics: Safety and Toxicity Considerations |
|
|
757 | (20) |
|
|
|
Maria Rosa Martinez-Larranaga |
|
|
|
|
|
|
55 Probiotics: Safety and Toxicity Considerations |
|
|
777 | (22) |
|
|
|
Maria Rosa Martinez-Larranaga |
|
|
|
|
|
|
56 Probiotics: Preclinical Testing for Verification of Their Gastrointestinal Effectiveness |
|
|
799 | (12) |
|
|
|
|
|
57 Synbiotics: Safety and Toxicity Considerations |
|
|
811 | (14) |
|
|
|
|
|
|
|
|
|
|
|
V Toxicity And Toxic Interactions |
|
|
|
58 Toxic Contamination of Nutraceuticals and Food Ingredients |
|
|
825 | (14) |
|
|
|
|
|
M. Concepcion Martin-Domingo |
|
|
59 Nutraceuticals and Adverse Outcome Pathways |
|
|
839 | (16) |
|
|
|
|
|
60 Interactions between Nutraceuticals/Nutrients and Therapeutic Drugs |
|
|
855 | (20) |
|
|
|
Maria Rosa Martinez-Larranaga |
|
|
|
|
|
|
61 Interactions between Chinese Nutraceuticals and Western Medicines |
|
|
875 | (8) |
|
|
|
|
|
|
|
62 Assessment of Genotoxic Effects of Selected Herbal Dietary Supplements |
|
|
883 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
63 Evaluation and Regulation of Food Supplements: European Perspective |
|
|
895 | (30) |
|
|
|
Maria Rosa Martinez-Larranaga |
|
|
|
|
|
|
64 Seed to Patient in Clinically Proven Natural Medicines |
|
|
925 | (8) |
|
|
|
65 Regulatory Aspects of Nutraceuticals: Japanese Perspective |
|
|
933 | (8) |
|
|
|
66 Regulatory Aspects of Nutraceuticals: An Indian Perspective |
|
|
941 | (6) |
|
|
|
|
|
|
|
67 Regulatory Aspects of Nutraceuticals: Chinese Perspective |
|
|
947 | (12) |
|
|
|
68 Regulatory Aspects of Nutraceuticals: Russian Perspective |
|
|
959 | (12) |
|
|
|
|
|
|
|
|
|
|
|
69 Nutraceuticals: Turkish Perspective |
|
|
971 | (12) |
|
|
|
|
| Index |
|
983 | |
Biežāk uzdotie jautājumi par e-grāmatām